Amgen's Kyprolis Miss In First-Line Myeloma Surprising, But Clinically Irrelevant
Because CLARION was designed to test Kyprolis head-to-head against fellow proteasome inhibitor Velcade, the failure could hurt the drug's standing in its class. But the trial design used a regimen largely phased out of clinical practice and Amgen has other chances to prove superiority.
You may also be interested in...
ASCO 2020, which takes place from 29-31 May, will necessarily depart from its predecessors in location, content and delivery. Here, with input from Biomedtracker and Datamonitor Healthcare, we take a look at what can be expected during this year’s late-breaking clinical trial sessions.
Proving a survival benefit in the head-to-head ENDEAVOR relapsed multiple myeloma study gives Amgen's Kyprolis a leg up ahead of the entry of Velcade generics in the US this year.
Amgen signaled future declines in revenue for its top-selling product Enbrel during its third quarter conference call as payer pressure on drug pricing and competition mounts.